Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Beijing Biotech
Parabilis Medicines, Inc.
Fred Hutchinson Cancer Center
Exscientia AI Limited
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Centre hospitalier de l'Université de Montréal (CHUM)
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
AstraZeneca
Agenus Inc.
858 Therapeutics, Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
Orano Med LLC
CHU de Quebec-Universite Laval
Filamon LTD
Centre Oscar Lambret
PMV Pharmaceuticals, Inc
AstraZeneca
Washington University School of Medicine
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
UMC Utrecht
Aveni Foundation
Psyence Australia Pty Ltd
ViroMissile, Inc.
Barbara Ann Karmanos Cancer Institute
Dana-Farber Cancer Institute
Duke University